Zenas BioPharma Inc. (ZBIO)
ZBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/0001104659-26-027964-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001953926 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.0M |
| Net income | -$377.7M |
| Operating income | -$383.1M |
| Net margin | -3777.4% |
| Operating margin | -3830.6% |
| Revenue growth | +100.0% |
| Cash | $110.6M |
| Total assets | $383.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 189.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $177.8M cash; operating cash flow -$60.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 67,817,793 (2026-10-30); 53,679,166 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-11-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $27.8M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.0M | -$108.9M | -$58.0M | $177.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.0M | -$111.5M | -$57.2M | $196.6M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$81.0M | -$75.2M | $500.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | $0 | -$240.4M | -$52.4M | $110.6M | $78.6M | $10.0M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $0 | -$51.5M | -$41.1M | $115.6M | $73.0M | $15.0M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$52.2M | -$41.7M | $44.0M | No debt tags | $15.0M | 10-Q 2025-08-12 |
| Q1 2025 2025-03-31 | $10.0M | -$33.6M | -$37.1M | $196.6M | No debt tags | $15.0M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $5.0M | -$52.6M | -$38.6M | $319.7M | No debt tags | $5.0M | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-03-16 |
Source: SEC EDGAR submissions feed, 196 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.9% |
| 1 month | +11.3% |
| 3 months | -4.1% |
| Year to date | -22.9% |
| 1 year | -21.5% |
| From 52-week high | -35.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics Inc. | $13.29 | -2.64% | $1.9B |
| MRVI | Maravai LifeSciences Holdings Inc. | $7.40 | -1.86% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
| ETON | Eton Pharmaceuticals Inc. | $63.88 | -0.08% | $1.8B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| ZYME | Zymeworks Inc. | $26.45 | +0.80% | $1.8B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier